News &amp; Updates

Use of the digital intervention BabyBreathe does not appear to significantly help pregnant women to continuously abstain from smoking postpartum when compared with usual care, a study has found.

Digital intervention no better than usual care for postpartum smoking cessation

Injectable HIV Tx trumps daily pill in virally suppressed adolescents

The week-96 LATA trial results demonstrate the superiority of long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) to tenofovir/lamivudine/dolutegravir (TLD) for maintaining virologic suppression in adolescents with HIV in sub-Saharan Africa.

Injectable HIV Tx trumps daily pill in virally suppressed adolescents

04 Sep 2026

CVD risk in lupus patients lower with anifrolumab vs belimumab

In the treatment of patients with systemic lupus erythematosus, anifrolumab is associated with reduced cardiovascular disease (CVD) risk compared with belimumab, as shown in a retrospective study.

CVD risk in lupus patients lower with anifrolumab vs belimumab

Lecanemab sustains benefit for AD in 3-year LEADER update

Three years post-initial US FDA approval, lecanemab still shows ongoing clinical benefits and reduces amyloid plaques in patients with early Alzheimer’s disease (AD).

Lecanemab sustains benefit for AD in 3-year LEADER update

04 Sep 2026

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

In patients with serious mental illness (SMI), initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with lower risks of all-cause mortality and major adverse cardiovascular events (MACEs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors, a large study has shown.

GLP-1 RAs outperform SGLT2 inhibitors in mortality risk reduction in patients with serious mental illness

$Patients with refractory epilepsy report reduced seizures with cannabis-based products$

Patients with refractory epilepsy report reduced seizures with cannabis-based products

The use of cannabis-based products for refractory epilepsy is associated with high perceived efficacy in a real-world public health setting in Brazil, with most patients reporting having their seizure frequency halved while experiencing mild-to-moderate adverse events (AEs).

Patients with refractory epilepsy report reduced seizures with cannabis-based products

Bariatric surgery outdoes GLP-1 RAs for weight loss

Patients with obesity achieve greater weight loss with bariatric surgery than glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and tirzepatide, a study has shown.

Bariatric surgery outdoes GLP-1 RAs for weight loss

Veligrotug improves outcomes, life quality in patients with thyroid eye disease

A five-infusion course of veligrotug, a full antagonist monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), over 12 weeks results in improved diplopia, proptosis, and disease activity and is well tolerated in patients with active thyroid eye disease (TED), as shown in the phase III THRIVE study. Moreover, the therapeutic effect persists through week 52.

Veligrotug improves outcomes, life quality in patients with thyroid eye disease

Antimicrobial TDM detects toxic concentrations in paediatric setting

Therapeutic drug monitoring (TDM) of antimicrobial agents in a paediatric setting succeeds in recognizing out-of-range serum drug concentrations (SDC), specifically for vancomycin and aminoglycosides, according to a single-centre study.

Antimicrobial TDM detects toxic concentrations in paediatric setting

Lenacapavir continues to serve its PURPOSE in OLE study

Twice-yearly subcutaneous lenacapavir continues to show high efficacy and is well tolerated among cisgender men and gender-diverse individuals in the open-label extension (OLE) of the PURPOSE 2 trial.

Lenacapavir continues to serve its PURPOSE in OLE study